VYNE - VYNE Therapeutics Inc. Stock Price, Fair Value and News

$2.42+0.06 (+2.54%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

VYNE Price Action

Last 7 days

-3.2%


Last 30 days

-39.5%


Last 90 days

-23.2%


Trailing 12 Months

14.7%

VYNE RSI Chart

MayJunJulAugSepOctNovDec2025Feb020406080100

VYNE Valuation

Market Cap

35.7M

Price/Earnings (Trailing)

-1.05

Price/Sales (Trailing)

72.41

EV/EBITDA

-0.57

Price/Free Cashflow

-1.19

VYNE Price/Sales (Trailing)

2022202320242025050100150

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

VYNE Fundamentals

VYNE Revenue

Revenue (TTM)

493.0K

Rev. Growth (Yr)

6.14%

Rev. Growth (Qtr)

-38.89%

201820202022202405M10M15M20M

VYNE Earnings

Earnings (TTM)

-34.0M

Earnings Growth (Yr)

-84.64%

Earnings Growth (Qtr)

-29.25%

20162018202020222024-250M-200M-150M-100M-50M0

VYNE Profitability

EBT Margin

-6885.29%

Return on Equity

-53.51%

Return on Assets

-44.62%

Free Cashflow Yield

-84.31%

VYNE Investor Care

Shares Dilution (1Y)

5.69%

Diluted EPS (TTM)

3.39

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
2017201820192020202120222023202402M4M6M8M10M12M14M16M18M20M22M
Net sales
YearQ1Q2Q3Q4
2024423.0K486.0K493.0K0
2023398.0K407.0K354.0K424.0K
2022879.0K710.0K744.0K477.0K
202116.0M11.0M5.9M931.0K
20201.9M13.6M16.8M21.0M
20192.8M2.0M1.2M443.0K
20184.3M4.1M3.8M3.6M
20171.1M1.6M2.3M4.6M
2016000674.0K
Get all data in R, Python etc through our Historical Stock Data APIs
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan-BET inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal inhibitor for the treatment of immuno-inflammatory indications; and FMX114, a combination gel formation of tofacitinib and fingolimod, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
 CEO
 WEBSITEvynetherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES12

VYNE Therapeutics Inc. Frequently Asked Questions


What is the ticker symbol for VYNE Therapeutics Inc.? What does VYNE stand for in stocks?

VYNE is the stock ticker symbol of VYNE Therapeutics Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of VYNE Therapeutics Inc. (VYNE)?

As of Wed Feb 05 2025, market cap of VYNE Therapeutics Inc. is 35.7 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VYNE stock?

You can check VYNE's fair value in chart for subscribers.

Is VYNE Therapeutics Inc. a good stock to buy?

The fair value guage provides a quick view whether VYNE is over valued or under valued. Whether VYNE Therapeutics Inc. is cheap or expensive depends on the assumptions which impact VYNE Therapeutics Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VYNE.

What is VYNE Therapeutics Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Feb 05 2025, VYNE's PE ratio (Price to Earnings) is -1.05 and Price to Sales (PS) ratio is 72.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VYNE PE ratio will change depending on the future growth rate expectations of investors.